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Abstract: Obesity and diabetes are independent risk factors for cardiovascular diseases, and they
are associated with the development of a specific cardiomyopathy with elevated myocardial oxygen
consumption (MVO2) and impaired cardiac efficiency. Although the pathophysiology of this
cardiomyopathy is multifactorial and complex, reactive oxygen species (ROS) may play an important
role. One of the major ROS-generating enzymes in the cardiomyocytes is nicotinamide adenine
dinucleotide phosphate (NADPH) oxidase 2 (NOX2), and many potential systemic activators of
NOX2 are elevated in obesity and diabetes. We hypothesized that NOX2 activity would influence
cardiac energetics and/or the progression of ventricular dysfunction following obesity. Myocardial
ROS content and mechanoenergetics were measured in the hearts from diet-induced-obese wild
type (DIOWT) and global NOK2 knock-out mice (DIOKO) and in diet-induced obese C57BL/6J mice
given normal water (DIO) or water supplemented with the NOX2-inhibitor apocynin (DIOAPO).
Mitochondrial function and ROS production were also assessed in DIO and DIOAPO mice. This study
demonstrated that ablation and pharmacological inhibition of NOX2 both improved mechanical
efficiency and reduced MVO2 for non-mechanical cardiac work. Mitochondrial ROS production was
also reduced following NOX2 inhibition, while cardiac mitochondrial function was not markedly
altered by apocynin-treatment. Therefore, these results indicate a link between obesity-induced
myocardial oxygen wasting, NOX2 activation, and mitochondrial ROS.
Keywords: obesity; ROS; NADPH-oxidase; myocardial oxygen consumption; metabolism;
cardiac efficiency
1. Introduction
Obesity, insulin resistance, and diabetes are independent risk factors for heart failure [1], and they
are associated with a distinct diabetic cardiomyopathy independent of coronary heart disease or
hypertension [2]. The pathophysiology behind this type of cardiomyopathy is far from elucidated,
but increased oxidative stress is suggested to play an essential role [3,4]. A major non-mitochondrial
source of ROS in cardiomyocytes are NADPH oxidases (NOXs). NOX2 is one of the main isoforms in
the cardiomyocyte and several potent activators of NOX2, such as hyperglycemia, hyperlipidemia,
angiotensin II, and cytokines [5,6], are known to be elevated in animals models of obesity and
diabetes [7]. Experimental studies have demonstrated NOX2 upregulation in terms of gene expression,
protein levels, and activity in the left ventricle of both type I [8–11] and type II [12–14] diabetic models.
Pharmacological and genetic strategies for reducing NOX2 activity have also been associated with
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amelioration of oxidative stress and other factors that are believed to contribute to the development
of diabetic cardiomyopathy, including fibrosis, ER stress markers, autophagy, and inflammation,
in combination with improved ventricular function [7].
Important hallmarks of diabetic cardiomyopathy are altered myocardial metabolism with increased
fatty acid oxidation [15–17], energy imbalance [15,18], impaired mechanoenergetic properties [19],
and increased myocardial oxygen consumption (MVO2) [20]. The underlying mechanisms for the
increase in MVO2 are not fully elucidated, but they may be linked to the increased fatty acid load [19]
or oxidation [21], impaired calcium handing [22], and/or mitochondrial dysfunction [23,24].
Whether increased NOX2-mediated signalling might influence obesity/diabetes-induced
impairments in myocardial metabolism and/or efficiency is not known. However, NOX2-signalling has
been shown to influence many of the same factors that are believed to contribute to myocardial oxygen
wasting in obesity/diabetes. These include changes in mitochondrial function and ROS production [25],
as well as altered activity of calcium-handling proteins and impaired calcium homeostasis [26–29].
In accordance with this, we have also shown an association between cardiac tissue ROS-content and
MVO2 in the hearts from diet-induced obese mice [23], suggesting a role for ROS in myocardial oxygen
wasting. Based on this, we hypothesize that genetic ablation and the pharmacological inhibition of
NOX2 may attenuate obesity-induced oxygen wasting in the myocardium.
2. Materials and Methods
2.1. Animals
Global NOX2 knock-out mice (NOX2 KO) and their wild-type littermates (WT) on a C57BL/6J
background, which were originally obtained from a colony established at King’s College, London, UK,
were bred locally. Five weeks old, male NOX2 KO mice (n = 16) and their wild-type male littermates
(WT, n = 14) were fed a high a fat diet (HFD; 60% kcal from fat, TestDiet, London, UK) for 28 weeks,
resulting in diet-induced obese mice (DIOKO and DIOWT, respectively). Age matched WT (n = 7)
and NOX2 KO (n = 7) mice that were fed a standard control diet served as lean controls (CONWT
and CONKO).
In another cohort of animals, obesity was induced in male C57BL/6J mice (Charles River
Laboratories, n = 42) by feeding them a Western, palatable diet for 18 or 28 weeks (WD, 35% kcal from
fat, TestDiet, London UK) starting at the age of 5–6 weeks. After seven weeks on this diet, the mice
were divided into two weight-matched groups receiving either normal water (DIO, n = 23) or water
supplemented with the NOX2 inhibitor; 2.4 g/L apocynin (DIOAPO, n = 19 [30]) for the rest of the
feeding periods. The age-matched mice were fed a standard control diet (CON, n = 22). Another subset
of mice (DIO, DIOAPO and CON, 6–7 mice per group) were included to study mitochondrial function.
The experiments were designed according to the guidelines from the Federation of European
Laboratory Animal Science Associations (FELASA), EU animal research directive (86/609/EEC), Council
of Europe (ETS 123), and the EU directive (2010/63/ EU). The local authority of the National Animal
Research Authority in Norway approved the ethical protocols (FOTS id: 4772 and 3946). The 3R’s
(Replacement, Reduction, and Refinement) have specifically been addressed when designing the study.
All mice received chow ad libitum, free access to drinking water, and they were housed at 23 ◦C.
2.2. Plasma Parameters
To test glucose tolerance, blood was collected from the saphenous vein in fasted (4 h) animals
and measured (glucometer, FreeStyle Lite, Alameda, CA) before (0 min.) and 15, 30, 60, 120 min.
after administration of a glucose solution (1.3 g/kg body wt i.p.). Plasma free fatty acids (FFA) were
analyzed using a commercial kit (NEFA-HR, Wako, Germany) and insulin was analyzed using ELISA
kits (DRG Diagnostics, Germany). Insulin resistance was evaluated while using the homeostatic model
assessment for quantifying insulin resistance (HOMA). This was calculated from the product of fasting
blood glucose and insulin (µU/mL), and then divided by 22.5 [31].
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2.3. Isolated Heart Perfusions
The isolated hearts were perfused with a modified KHB buffer supplemented with 0.5 mM
palmitate bound to 3% BSA. Myocardial glucose and fatty acid oxidation rates were measured in
isolated perfused working hearts, while using radio-labelled isotopes [15]. Stroke work (SW) and
parameters of left ventricular (LV) function were assessed by a 1.0 F micromanometer-conductance
catheter. Myocardial oxygen consumption (MVO2) was measured using fiber-optic oxygen probes,
as previously described [19]. The relationship between cardiac work and MVO2 was used to evaluate
mechanical efficiency [19]. MVO2 was also measured in unloaded, retrograde-perfused hearts
before (MVO2 unloaded) and after KCl-arrest, to measure oxygen cost for basal metabolism (MVO2 BM).
Based on these measurements, we also calculated the oxygen consumption for processes related to
excitation-contraction coupling (MVO2 ECC) [20].
2.4. Assessment of ROS Production in Myocardial Tissue
ROS production was assessed while using the dihydroethidium-high pressure liquid
chromatography (DHE-HPLC) method, as described before [32]. Briefly, fresh LV tissue (58.7 ± 2.5 mg)
was incubated with 100 µM DHE in PBS containing 100µM DTPA for 30 min. at 37 ◦C. The samples
were quickly washed with PBS/DTPA, resuspended in cold acetonitrille and sonicated (3 × 8 W, 5 sec).
The homogenates were centrifuged at 13,000 rpm for 10 min. and the supernatant collected in a new
tube and dried under vacuum while using a SpeedVacuum (ThermoScientific). The dried pellet was
frozen at −80 ◦C and further resuspended in PBS/DTPA and then injected into a HPLC system (Dionex,
UltiMate 3000, London, UK). DHE was monitored by ultraviolet absorption at 245 nm and either
hydroxyethidium (EOH) and ethidium (E) were monitored by fluorescence detection with excitation
510 nm and emission 595 nm. Here, the DHE-derived products are expressed as ratios of EOH and E
per DHE consumed per gram of wet weight tissue.
2.5. Mitochondrial Function and ROS Production
In a follow-up study, we sought to investigate the mitochondrial effects of NOX2 inhibition by
apocynin treatment of C57BL/6J fed a WD for 28 weeks (CON, DIO, and DIOAPO mice). Isolated cardiac
mitochondria were obtained from freshly harvested LV tissue while using a slight modification of the
method of Palmer et al. [33], and mitochondrial function was measured in an oxygraph (Oxygraph 2k,
Oroboros Instruments, Austria). The experiments were performed using malate (2.5 mM), glutamate
(5mM) and pyruvate (10mM, PG), or malate (2.5 mM) and palmityol-carnitine (10mM, PC) as substrates.
Mitochondrial leak state was determined before ADP addition (Leak). A saturated amount of ADP was
then added to induce maximal mitochondrial respiration capacity (OXPHOS). Cytochrome C was added
to the chambers (10 µM) to evaluate the integrity of mitochondrial membranes. H2O2 production was
also assessed in respiring mitochondria while using Amplex UltraRed (AmR, 10 µM) dye. The reaction
of H2O2 and AmR was catalyzed by horseradish peroxidase (10 uU) to produce a red fluorescent
compound (recorded by the Fluo LED2-Module in Oxygraph 2k). The AUR signal was calibrated
during the protocols using a fixed amount of H2O2 (10 µM). Exogenous SOD (5 µM) was added to
reduce any remaining O2− to H2O2. The rates of respiration and ROS production were adjusted to
protein content and experiments were performed at 37 ◦C.
2.6. Real-Time Quantitative PCR
RNA was isolated from perirenal white adipose tissue (PWAT), stored in Allprotect Tissue
Reagent, and then measured using the RNeasy Lipid Tissue Mini Kit protocol (Qiagen, Hilden,
Germany). The liver samples were stored in RNA later (Qiagen, Hilden, Germany) at −20 ◦C until the
isolation of RNA by RNeasy Fibrous Mini Kit protocol with a small modification (the Proteinase K
step was removed). The RNA concentration and purity were determined using spectrophotometry
(NanoDrop 2000, Thermo Fisher, Waltham, MA, USA). 200 ng (PWAT) or 1000 ng (liver) of RNA was
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reverse-transcribed into cDNA while using High Capacity cDNA Reverse Transcription Kit (Thermo
Fisher, Waltham, MA, USA). Real-time PCR was performed in a LightCycler®96 System (Roche, Basel,
Switzerland), where we pipetted 5 ng (PWAT) or 12.5 ng (liver) of cDNA and FastStart Essential DNA
Green Master (Roche, Basel, Switzerland). Our target genes were Tumor necrosis factor-alpha (Tnfα)
and NOX2 (Nox2). Tnfα (NM_013693.3) forward primer: CAT-CTT-CTC-AAA-ATT-CGA-GTG-ACA-A
and reversed primer: TGG-GAG-TAG-ACA-AGG-TAC-AAC-CC. Nox2 (NM_007807.5) forward
primer: TGAATGCCAGAGTCGGGATT and reversed primer: CCC-CCT-TCA-GGG-TTC-TTG-ATT-T.
The target gene expression levels were normalized to hypoxanthine phosphoribosyltransferase 1
(Hprt1, NM_013556.2) detected by forward primer: TCC-TCC-TCA-GAC-CGC-TTT-T and reverse
primer: CCT-GGT-TCA-TCA-TCG-CTA-ATC. The stability of the housekeeping gene was determined
by geNorm [34].
2.7. Statistical Analysis
The data are expressed as mean ± SEM. Differences between groups were analysed using a
One-Way ANOVA. A post-hoc test (Holm-Sidak method) was used with multiple comparisons between
groups when using different genotypes (CONWT, CONKO, DIOWT and DIOKO) and comparison against
a control (DIO) when using the same genotype (CON, DIO and DIOAPO). The overall significance level
was set to p < 0.05. The differences between diets within the same genotype and differences between
genotypes within the same diet are indicated within the tables and figures.
3. Results
3.1. Effect of NOX2 Ablation and Inhibition on Obesity, Glucose Tolerance and Inflammatory Status
Obesity promotes a low-grade chronic inflammation, which is associated with insulin resistance
in mice. Therefore, we assessed both insulin resistance and a marker of hepatic and adipose tissue
inflammation. Following 28 weeks on a HFD, DIOWT and DIOKO displayed similar gain in body-weight,
PWAT, and liver weight when compared to their respective lean genotypes (CONWT and CONKO,
Table 1). An analysis of liver and white adipose tissue also showed increased hepatic and PWAT
mRNA expression of NOX2 and the inflammatory marker TNFα (Table 1) in DIOWT mice. Knocking
down NOX2 did not reduce the hepatic expression of tnfα following obesity in DIOKO compared to
DIOWT mice (Table 1). However, PWAT tnfα expression was significantly reduced in DIOKO mice
(Table 1), suggesting reduced adipose inflammation. The plasma levels of glucose and FFA were not
different between groups, while fasted plasma insulin and HOMA-indexes were elevated in DIOWT as
compared to CONWT. Although there was also a trend towards reduced HOMA-IR in DIOKO when
compared to CONKO, this did not reach statistical significance.
Apocynin was added to the drinking water in order to reduce NOX2 activity in obese C57BL/6J
mice to further study the effects of NOX2-activity in obesity. We used two time-points, 18 and 28 weeks
of western diet (WD) feeding, in order to follow the development of obesity and systemic effects of
NOX2 inhibition. In the first six weeks of apocynin treatment, body weight gain was significantly lower
in DIOAPO when compared to untreated DIO mice (data not shown), but, at the 18 week time-point,
there were no measurable effects of apocynin-treatment on obesity, liver, or PWAT weight (Table 2).
However, there was an increased glucose tolerance and reduced levels of circulating FFA in DIOAPO
mice as compared to non-treated DIO mice at this time point (Table 2). Weight gain increased to
a similar extent in DIO and DIOAPO mice following 28 weeks of WD However, liver weights were
reduced by apocynin-treatment (Table 2). Glucose tolerance was not attenuated by apocynin treatment
in DIOAPO mice and, surprisingly, plasma FFA was not different between groups at this time-point
(Table 2).
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Table 1. Animal characteristics of wild type (WT) and global NOX2 knock-out (KO), control mice









Body weight (g) 35.1 ± 1.8 35.0 ± 1.0 50.8 ± 1.2 * 49.4 ±1.4 *
Heart weight (mg) 158 ± 3 159± 4 177 ± 6 * 183 ± 5 *
PWAT weight (g) 0.70 ± 0.12 0.61 ± 0.04 0.21 ± 15 * 0.22 ± 0.19 *
Nox2PWAT 1.0 ± 0.2 n.d. 5.0 ± 1.2 * n.d.
TnfαPWAT 1.0 ± 0.2 0.7 ± 0.1 10.2 ± 2.6 * 3.0 ± 0.6 *,#
Liver weight (g) 1.7 ± 0.2 1.5 ± 0.1 2.7 ± 0.2 * 2.6 ± 0.2 *
Nox2liver 1.0 ± 0.2 n.d. 1.9 ± 0.3 * n.d.
Tnfα liver 1.0 ± 0.3 0.9 ± 0.2 2.9 ± 0.4 * 2.8 ± 0.3 *
Plasma FFA fed (µM) 532 ± 112 967 ± 292 835 ± 96 1057 ± 260
Blood glucose fasted (mmol/L) 5.6 ± 0.2 7.0 ± 0.1 6.6 ± 0.5 7.1 ± 0.3
Insulin fasted (µU/mL) 1.7± 0.3 2.1 ± 0.4 6.5 ± 1.5 * 4.5 ± 0.5
HOMA-IR 2 ± 1 3 ± 1 30 ± 13 * 13 ± 3
Blood samples were obtained from n = 5–10 per group. Perirenal white adipose tissue (PWAT), free fatty acids
(FFA). The mRNA expression of genes encoding for tumor necrosis factor α (Tnfα) and NADPH oxidase 2 (NOX2),
was normalized to the corresponding expression in CONWT. Values are means ± SEM. * p < 0.05 CON vs. DIO
within the same genotype. # p < 0.05 between genotypes in the same diet.
Table 2. Animal characteristics of chow fed controls (CON) and diet-induced obese C57BL/6J mice
with or without apocynin treatment (DIO and DIOAPO).





Body weight (g) 30.1 ± 0.4 42.7 ± 1.2 * 40.1 ± 1.8
Heart weight (mg) 134 ± 3 144 ± 4 * 149 ± 6
PWAT weight (g) 0.2 ± 0.2 1.0 ± 0.7 * 0.8 ± 1.1
Liver weight (g) 1.1 ± 0.1 1.7 ± 0.2 * 1.4 ± 0.1
Plasma FFA fed (µM) 638 ± 88 1086 ± 143 * 648 ± 88 #
Blood glucose fasted (mM) 4.7 ± 0.2 5.1 ± 0.2 4.7 ± 0.1
Glucose tolerance test (AUC) 603 ± 45 945 ± 57 * 761 ± 52 #
28 Weeks of Diet n = 8–10 n = 8–14 n = 8–10
Body weight (g) 31.6 ± 0.8 49.9 ± 1.2 * 46.5 ± 1.6
Heart weight (mg) 139 ± 4 158 ± 3 * 154 ± 4
PWAT weight (g) 0.4 ± 0.7 1.4 ± 0.6 * 1.2 ± 83
Liver weight (g) 1.1 ± 0.1 2.4 ± 0.2 * 1.8 ± 0.2 #
Plasma FFAfed (µM) 583 ± 44 637 ± 74 655 ± 39
Blood glucose fasted (mM) 5.6 ± 0.3 6.0 ± 0.3 5.8 ± 0.3
Glucose tolerance test (AUC) 747 ± 55 926 ± 50 * 861 ± 67
Blood samples were obtained from 16–22 mice per group (18wk) and 10–14 in per group (28wk). Perirenal white
adipose tissue (PWAT), area under curve (AUC). The values are means ± SEM. * p < 0.05 CON vs. DIO, # p < 0.05
DIO vs. DIOAPO.
Together, these data suggest modest systemic effects of both NOX2 ablation and inhibition with a
slight increase in glucose tolerance as well as an improved low-grade adipose inflammatory response
to diet-induced obesity.
3.2. Effects of Obesity and NOX Inhibition on Myocardial Reactive Oxygen Species
Pieces of left ventricular (LV) tissue were incubated with DHE, and the fluorescence of the products
hydroxyethidium (EOH) and ethidium (E) were measured using HPLC, in order to examine whether
ablation or inhibition of NOX2 activity could reduce cardiac ROS-content. The EOH product is a
specific superoxide-derived DHE product, and was increased in cardiac tissue from both models of
obesity following 28 weeks of obesogenic diet when compared to their lean controls. The ablation
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and inhibition of NOX2 reduced the EOH product in cardiac tissue following obesity (Figure 1A,B).
The ethidium product (which relates to other ROS) was not significantly elevated in ventricular tissue
from obese mice or influenced by NOX2 ablation or inhibition (Figure 1C,D).
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Figure 1. Reactive oxygen species-products hydroxyethidium (EOH) and ethidium (E) per 
dihydroethidium (DHE) consumed in cardiac tissue from lean controls (CONWT and CONKO) and 
obese (DIOWT and DIOKO) wild type and NOX2 KO mice fed a high fat diet for 28 weeks (A and C). 
Also shown in lean (CON), obese (DIO), and apocynin-treated obese (DIOAPO) C57BL/6J mice fed a 
western diet for 28 weeks (B and D) n = 4–8 in each group. Values are normalized to EOH in lean 
controls. Single values and means ± SEM.* p < 0.05 CON vs DIO within same genotype, # p < 0.05 
DIOWT vs DIOKO and DIO vs DIOAPO. 
3.3. Effects of NOX2 Ablation and Inhibition on Ventricular Function 
Twenty-eight weeks of HFD induced LV dysfunction in DIOWT mice. This was mainly a diastolic 
dysfunction, being illustrated by increased LV end-diastolic pressure (LVEDP) and end-diastolic 
pressure-volume relationships (EDPVR, Table 3). However, obesity-induced diastolic dysfunction 
was abrogated in DIOKO mice, as these hearts exhibited reduced LVEDP and EDPVR when compared 
to DIOWT (Table 3). In addition, the LV relaxation time-constant (Tau) was significantly lower in 
DIOKO as compared to DIOWT hearts, suggesting improved early LV diastolic function (Table 3). 
Although the parameters of LV systolic function (such as dP/dt max and Preload Recruitable Stroke 
Work index, PRSWi) were not significantly different between groups, we found cardiac output to be 
modestly increased in DIOKO as compared to DIOWT (Table 3). 
Table 3. Steady state and load-independent parameters of left-ventricular (LV) function obtained in 
isolated perfused working hearts from wild type (WT) and global NOX2 knock out (KO) control mice 
(CON) and diet-induced obese mice (DIO) given an obesogenic diet for 28 weeks. 
 
CONWT 
n = 6 
CONKO 
n = 5 
DIOWT 
n = 6–11 
DIOKO 
n = 8–10 
Cardiac output (mL/min)  11.6 ± 0.6 11.8 ± 0.9 10.9 ± 0.4 12.2 ± 0.2# 
Coronary flow (mL/min) 4.0 ± 0.3 3.5 ± 0.3 3.8 ± 0.3 3.7 ± 0.2 
Heart rate (bpm) 418 ± 1 408 ± 10 419 ± 7 413 ± 6 
dP/dtmax (mmHg/sec) 3515 ± 259 3093 ± 126 3785 ± 230 3806 ± 143 
dP/dtmin (mmHg/sec) −2982 ± 215 −2611 ± 106 −3134 ± 174 −3230 ± 110 
Tau Weiss (msec) 10.8 ± 0.3 11.7 ± 0.3 11.7 ± 0.8 10.4 ± 0.3 # 
LVEDP (mmHg) 7.9 ± 0.8 8.6 ± 0.6 12.5 ± 1.2 * 9.7 ± 0.7 # 
LVDP (mmHg) 59 ± 2 59 ± 1 65 ± 2 66 ± 2 
LVEDV (μL) 105 ± 4 106 ± 13 76 ± 14 97 ± 4 
EDPVR (mmHg/μL) 0.12 ± 0.01 0.14 ± 0.01 0.24 ± 0.04 * 0.11 ± 0.01 # 
PRSWi 34.0 ± 1.1 28.8 ± 2.1 30.1 ± 2.9 36.7 ± 2.4 
Hearts were paced at 10% above intrinsic heart rate. Steady state parameters were obtained at a pre- 
and afterload of 8 and 50 mmHg, respectively. LV end-diastolic pressure (LVEDP), developed 
pressure (LVDP) and end-diastolic volume (LVEDV), maximum positive and negative first time 
derivative of LV pressure (dP/dtmax and dP/dtmin), LV relaxation time constant (Tau). Load-independent 
Figure 1. Reactive oxygen species-products hydroxyethidium (EOH) and ethidium (E) per
dihydroethidium (DHE) consumed in cardiac tissue from lean controls (CONWT and CONKO) and
obese (DIOWT and DIOKO) wild type and NOX2 KO mice fed a high fat diet for 28 weeks (A,C).
Also shown in lean (CON), obese (DIO), and apocynin-treated obese (DIOAPO) C57BL/6J mice fed a
western diet for 28 weeks (B,D) n = 4–8 in each group. Values are normalized to EOH in lean controls.
Single values and means ± SEM. * p < 0.05 CON vs. DIO within same genotype, # p < 0.05 DIOWT vs.
DIOKO and DIO vs. DIOAPO.
3.3. Effects of NOX2 Ablation and Inhibition on Ventricular Function
Twenty-eight weeks of HFD induced LV dysfunction in DIOWT mice. This was mainly a diastolic
dysfunction, being illustrated by increased LV end-diastolic pressure (LVEDP) and end-diastolic
pressure-volume relationships (EDPVR, Table 3). However, obesity-induced diastolic dysfunction was
abrogated in DIOKO mice, as these hearts exhibited reduced LVEDP and EDPVR when compared to
DIOWT (Table 3). In addition, the LV relaxation time-constant (Tau) was significantly lower in DIOKO
as compared to DIOWT hearts, suggesting improved early LV diastolic function (Table 3). Although the
parameters of LV systolic function (such as dP/dt max and Preload Recruitable Stroke Work index,
PRSWi) were not significantly different between groups, we found cardiac output to be modestly
increased in DIOKO as compared to DIOWT (Table 3).
Eighteen weeks of WD did not induce LV dysfunction in DIO mice, as the parameters of LV
function were similar between groups (Table 4). Twenty-eight weeks of WD induced both LV systolic
and diastolic dysfunction, being evident as lower cardiac output, reduced dP/dtmin, increased relaxation
factor (Tau) and EDPVR in DIO when compared to CON hearts (Table 4). Apocynin treatment increased
LV systolic and diastolic function in DIOAPO mice, evident as increased cardiac output and PRSWi,
together with the normalization of EDPVR relationships (Table 4).
Analysis of the relationship between LV end-diastolic pressure (LVEDP) and volume (LVEDV) at
three different workloads showed a left and upwards shift of this relationship in DIO hearts following
28 weeks of obesogenic diet (Figure 2A,C), thus suggesting LV concentric remodeling. This was
attenuated by both NOX2 ablation (DIOKO, Figure 2A) and by apocynin treatment (DIOAPO, Figure 2C).
Ventricular volumes and pressures were not different between groups following 18 weeks of WD
(Figure 2B).
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Table 3. Steady state and load-independent parameters of left-ventricular (LV) function obtained in
isolated perfused working hearts from wild type (WT) and global NOX2 knock out (KO) control mice









Cardiac output (mL/min) 11.6 ± 0.6 11.8 ± 0.9 10.9 ± 0.4 12.2 ± 0.2#
Coronary flow (mL/min) 4.0 ± 0.3 3.5 ± 0.3 3.8 ± 0.3 3.7 ± 0.2
Heart rate (bpm) 418 ± 1 408 ± 10 419 ± 7 413 ± 6
dP/dtmax (mmHg/sec) 3515 ± 259 3093 ± 126 3785 ± 230 3806 ± 143
dP/dtmin (mmHg/sec) −2982 ± 215 −2611 ± 106 −3134 ± 174 −3230 ± 110
Tau Weiss (msec) 10.8 ± 0.3 11.7 ± 0.3 11.7 ± 0.8 10.4 ± 0.3 #
LVEDP (mmHg) 7.9 ± 0.8 8.6 ± 0.6 12.5 ± 1.2 * 9.7 ± 0.7 #
LVDP (mmHg) 59 ± 2 59 ± 1 65 ± 2 66 ± 2
LVEDV (µL) 105 ± 4 106 ± 13 76 ± 14 97 ± 4
EDPVR (mmHg/µL) 0.12 ± 0.01 0.14 ± 0.01 0.24 ± 0.04 * 0.11 ± 0.01 #
PRSWi 34.0 ± 1.1 28.8 ± 2.1 30.1 ± 2.9 36.7 ± 2.4
Hearts were paced at 10% above intrinsic heart rate. Steady state parameters were obtained at a pre- and afterload
of 8 and 50 mmHg, respectively. LV end-diastolic pressure (LVEDP), developed pressure (LVDP) and end-diastolic
volume (LVEDV), maximum positive and negative first time derivative of LV pressure (dP/dtmax and dP/dtmin),
LV relaxation time constant (Tau). Load-independent parameters; the slope of LV end-diastolic-pressure-volume
relationships (EDPVR) and Preload Recruitable Stroke Work index (PRSWi) were obtained by a temporary preload
reduction. Values are means ± SEM. * p < 0.05 within the same genotype. # p < 0.05 between genotypes in the
same diet.
Table 4. Steady state and load-independent parameters of left-ventricular (LV) function obtained in
isolated perfused working hearts from chow-fed controls (CON) and diet-induced obese C57BL/6J mice
with or without apocynin treatment (DIO and DIOAPO).





Aortic flow (mL/min) 10.8 ± 0.4 10.1 ± 0.6 10.7 ± 0.1
Coronary flow (mL/min) 3.0 ± 0.2 3.3 ± 0.2 3.3 ± 0.3
Heart rate (bpm) 396 ± 11 359 ± 17 399 ± 13
dP/dtmax (mmHg/sec) 3749 ± 138 3925 ± 65 3615 ± 159
dP/dtmin (mmHg/sec) −2854± 105 −2961 ± 89 −2863 ± 131
Tau Weiss (msec) 11.0 ± 0.6 11.0 ± 0.4 11.3 ± 0.5
LVEDP (mmHg) 7.8 ± 1.1 8.5 ±1.1 9.0 ± 1.8
LVDP (mmHg) 57 ± 2 59 ± 2 57 ± 3
LVEDV (µL) 72 ± 10 58 ± 13 55 ± 14
EDPVR (mmHg/µL) 0.16 ± 0.01 0.19 ± 0.01 0.19 ± 0.04
PRSWi 29.9 ± 1.8 24.4 ± 1.2 27.4 ± 3.3
28 Weeks of Diet n = 7 n = 9 n = 8
Aortic flow (mL/min) 12.5 ± 0.3 9.4 ± 0.9 * 12.1 ± 0.1 #
Coronary flow (mL/min) 3.2 ± 0.2 3.5 ± 0.2 3.2 ± 0.3
Heart rate (bpm) 434 ± 11 404 ± 9 415 ± 0.8
dP/dtmax (mmHg/sec) 3968 ± 50 3697 ± 121 * 3935 ± 92
dP/dtmin (mmHg/sec) −3142± 51 −2735 ± 116 * −2948 ± 68
Tau Weiss (msec) 10.0 ± 0.2 11.3 ± 0.4 * 10.8 ± 0.3
LVEDP (mmHg) 9.3 ± 0.6 10.7 ± 0.9 10.3 ± 0.6
LVDP (mmHg) 59 ± 1 56 ± 1 58 ± 1
LVEDV (µL) 94 ± 6 67 ± 8 * 87 ± 2 #
EDPVR (mmHg/µL) 0.18 ± 0.01 0.30 ± 0.04 * 0.18 ± 0.02 #
PRSWi 28.3 ± 2.7 23.7 ± 2.4 32.4 ± 1.5 #
The hearts were paced at 10% above intrinsic heart rate. Steady state parameters were obtained at a pre- and
afterload of 8 and 50 mmHg, respectively. LV end-diastolic pressure (LVEDP), developed pressure (LVDP) and
end-diastolic volume (LVEDV), maximum positive and negative first time derivative of LV pressure (dP/dtmax
and dP/dtmin), LV relaxation time constant (Tau). Load-independent parameters including the slope of LV
end-diastolic-pressure-volume relationships (EDPVR) and Preload Recruitable Stroke Work index (PRSWi) were
obtained by a temporary preload reduction. Values are means ± SEM. * p < 0.05 CON vs. DIO. # p < 0.05 DIO
vs. DIOAPO.
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3.4. Effects of NOX2 Ablation and Inhibition on Myocardial Energetics 
Reduced LV mechanical efficiency (stroke work/MVO2) in hearts following obesogenic diets has 
been reported in several studies [23,34]. Here, we observed a trend towards reduced mechanical 
efficiency in DIO hearts following 18 weeks of WD (Figure 3B), with a significant reduction of LV 
mechanical efficiency in DIO when compared to CON hearts following 28 weeks of WD (Figure 3C). 
Ablation and inhibition of NOX2 both significantly increased mechanical efficiency in the hearts from 
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to contribute to increased LV mechanical efficiency following NOX2 ablation and inhibition after 28 
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Figure 2. Steady state left ventricular end-diastolic volumes (LVEDV) and pressures (LVEDP) at three
different workloads (preload: 4,6 and 8 mmHg and afterload: 50mmHg) from lean controls (CONWT
and CONKO) and obese (DIOWT and DIOKO) wild type and NOX2 KO mice fed a high fat diet for
28 weeks (A), as well as lean (CON), obese (DIO) and apocynin-treated obese (DIOAPO) C57BL/6J mice
fed a western diet for 18 (B) and 28 weeks (C). n = 5–10 per group, the values are mean ± SEM.
3.4. Effects of NOX2 Ablation and Inhibition on Myocardial Energetics
Reduced LV mechanical efficiency (stroke work/MVO2) in hearts following obesogenic diets has
been reported in several studies [23,34]. Here, we observed a trend towards reduced mechanical
efficiency in DIO hearts following 18 weeks of WD (Figure 3B), with a significant re ction of LV
mechanical efficiency in DIO when compared to CON hearts following 28 weeks of WD (Fig re 3C).
Ablation and inhibition of NOX2 bot significantly increased mechanical efficiency in the hearts from
obese mice (Figure 3A–C). The differences in LV mechanical efficiency were due to differences in
MVO2 at the 18-week timepoint (Figure 3E), while both reduced MVO2 and increased SW seemed to
contribute to increased LV mechanical efficiency follo ing NOX2 ablation and inhibition after 28 weeks
of obesogenic diets.
Obesity and diabetes have previously also been associated with elevated myocardial oxygen costs
for non-mechanical processes (MVO2unloaded) [23,35], which includes oxygen consuming processes
that are associated with excitation-contraction coupling (ECC) and basal metabolism (BM) to maintain
cellular homeostasis [20,23]. In line with the changes in mechanical efficiency, DIOKO hearts also
exhibited reduced MVO2unloaded compared to DIOWT hearts when completely unloaded of mechanical
work (Figure 4A). This was also found in DIOAPO hearts when compared to DIO hearts at both
time points (Figure 4B,C). The reduced MVO2unloaded in DIOKO hearts was associated with reduced
myocardial oxygen consumption for ECC (MVO2ECC, Figure 4D), and also found in DIOAPO after
18 weeks of obesogenic diet (Figure 4E). There were only subtle changes in the MVO2 for basal
metabolism between groups (MVO2BM, Figure 4G,H). At the 28-week time point, both changes in
MVO2ECC and MVO2BM (Figure 4F,I) seemed to contribute to a reduced obesity-induced oxygen
wasting in unloaded hearts from DIOAPO mice.
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Figure 3. Left ventricular mechanical efficiency (A–C) expressed as stroke-work (SW, G–I) relative
to myocardial oxygen consumption (D–F) in hearts from lean controls (CONWT and CONKO) and
diet-induced obese (DIO) wild type and NOX2 KO mice (DIOWT and DIOKO) fed a high fat diet for
28 weeks (A,D,G) as well as lean controls (CON) and untreated and apocynin-treated obese C57BL/6J
mice (DIO and DIOAPO) fed a western diet for 18 weeks (B,E,H) or 28 weeks (C,F,I). Single values and
means ± SEM. * p < 0.05 CON vs. DIO within same genotype, # p < 0.05 DIOWT vs. DIOKO and DIO
vs. DIOAPO.
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fed a western diet for 18 weeks (B, E, and H) or 28 weeks (C, F, and I). Single values and means ± 
SEM. * p < 0.05 within the same genotype, # p < 0.05 between genotypes within the same diet. 
3.5. Effects of NOX2 Inhibition on Myocardial Substrate Utilization and Mitochondrial Function 
Myocardial glucose oxidation rates were markedly down in DIO as compared to CON hearts 
following 18 weeks of WD with a concomitant increase in palmitate oxidation rates. We did not find 
apocynin treatment to alter substrate oxidation rates (Figure 5). 
  
Figure 4. Myocardial oxygen consumption in mechanically unloaded hearts (MVO2unloaded, A–C) and
for processes associated with excitation-contraction coupling (MVO2ECC, D–F) and basal metabolism
(MVO2BM, G–I) that was obtained from lean controls wild-type (CONWT) and NOX2-KO mice (CONKO)
and obese mice fed a high f t diet f r 28 weeks (DIOWT and DIOKO). (A,D,G). Also shown in lean
co trols (CON) and untreated and apocynin-treated obese C57BL/6J mice (DIO and DIOAPO) that were
fed a we tern diet for 18 weeks (B,E,H) or 28 we ks (C,F,I). Single values and me s ± SEM. * p < 0.05
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3.5. Effects of NOX2 Inhibition on Myocardial Substrate Utilization and Mitochondrial Function
Myocardial glucose oxidation rates were markedly down in DIO as compared to CON hearts
following 18 weeks of WD with a concomitant increase in palmitate oxidation rates. We did not find
apocynin treatment to alter substrate oxidation rates (Figure 5).
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Figure 5. Glucose (A) and palmitate (B) oxidation rates measured in isolated working hearts from lean
controls (CON), diet-induced obese (DIO), and obese apocynin-treated (DIOAPO) C57BL/6J mice fed an
obesogenic western diet for 18 weeks. Single values and mean ± SEM, * p < 0.05 vs. DIO.
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We further studied the mitochondrial function in ventricular tissue from CON, DIO, and DIOAPO
mice that were fed a WD for 28 weeks. The respiration rates were measured while using pyruvate and
glutamate (PG) or palmityol-carnitine (PC) as substrates. There were no significant changes in Leak or
OXPHOS states when using PG or PC as substrates in isolated cardiac mitochondria (Figure 6A,B,D–E).
Respiratory control ratios (OXPHOS/Leak) were not significantly different between groups when using
PG as substrates (Figure 6C), but significantly higher in the mitochondria from DIOAPO hearts when
using PC as substrates. There was also with a borderline difference between CON and DIO (p = 0.08,
Figure 6F).
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Figure 6. Oxygen fluxes (leak and maximal mitochondrial respiration capacity, OXPHOS) and 
respiratory coupling ratio (RCR) in isolated cardiac mitochondria using pyruvate and glutamate (PG, 
A–C) or palmityol-carnitine as substrates (PC, D–F). Mitochondria were obtained from lean controls 
(CON), untreated and apocynin-treated obese C57BL/6J mice (DIO and DIOAPO) fed a western diet for 
28 weeks. Single values and mean ± SEM, # p < 0.05 DIO vs DIOAPO. 
Finally, we assessed ROS production in isolated cardiac mitochondria. When adjusting the ROS 
production for mass or O2 flux (respiration rate), we found increased ROS production in the leak state 
in mitochondria from DIO hearts when using PG and PC as substrates. This obesity-induced ROS 
production was attenuated following apocynin treatment (DIOAPO, Figure 7A and B). Similar results 
were found for ROS production in the OXPHOS states. In general, the mass-specific ROS production 
tended to be higher in the leak states than in the OXPHOS state within groups, while mitochondria 
respiring on PG exhibited higher ROS production than when respiring on PC (p < 0.001). 
Figure 6. Oxygen fluxes (leak and maximal mitochondrial respiration capacity, OXPHOS) and
respiratory coupling ratio (RCR) in isolated cardiac mitochondria using pyruvate and glutamate (PG,
A–C) or palmityol-carnitine as substrates (PC, D–F). Mitochondria were obtained from lean controls
(CON), untreated and apocynin-treated obese C57BL/6J mice (DIO and DIOAPO) fed a western diet for
28 weeks. Single values and mean ± SEM, # p < 0.05 DIO vs. DIOAPO.
Finally, we assessed ROS production in isolated cardiac mitochondria. When adjusting the ROS
production for mass or O2 flux (respiration rate), we found increased ROS production in the leak state
in mitochondria from DIO hearts when using PG and PC as substrates. This obesity-induced ROS
production was attenuated following apocynin treatment (DIOAPO, Figure 7A,B). Similar results were
found for ROS production in the OXPHOS states. In general, the mass-specific ROS production tended
to be higher in the leak states than in the OXPHOS state within groups, while mitochondria respiring
on PG exhibited higher ROS production than when respiring on PC (p < 0.001).
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treated obese C57BL/6J mice (DIO and DIOAPO) fed a western diet for 28 weeks. Single values and 
means ± SEM, * p < 0.05 CON versus DIO, # p < 0.05 DIO vs DIOAPO. 
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first time, we were able to demonstrate that the obesity-mediated increase in myocardial oxygen 
wasting was prevented in both NOX2-KO mice and by NOX2-inhibition with apocynin. We also 
demonstrated a possible cross-talk between NOX2-activation and mitochondrial ROS-production, as 
has been previously suggested. 
Apocynin-treatment and NOX2-ablation have been associated with reduced obesity in several 
studies on mice while using different ages, types of obesogenic diets, and feeding periods [30,36–38]. 
Many studies have also suggested NOX2-derived oxidative stress to be involved in the progression 
of obesity and pre-diabetes, through impaired glucose tolerance [30,37,39,40], insulin resistance [39], 
dyslipidemia [37,38,40], and visceral adipose inflammation [30,36]. However, there are discrepancies 
regarding the systemic effects of NOX2 activity in obesity, with one study also reporting adverse 
systemic effects, such as hyperphagia, elevated obesity, hepatic steatosis, and inflammation, together 
with exacerbated insulin resistance in obese NOX2 KO mice [41]. The present study does not show 
major effects of reduced NOX2 activity on body weight gain while using long term obesogenic diets, 
but the data do suggest a transient reduction following the start of the apocynin-treatment. This is in 
line with previous studies using shorter feeding periods and similar apocynin-treatments of DIO 
mice [30,38]. Additionally, reduced NOX2 activity seemed to improve glucose tolerance, reduce 
hyperlipidemia, and reduce adipose inflammation following obesity to some degree, in accordance 
with previous studies [30,36]. We did not find NOX2 ablation to reduce the expression of these 
inflammatory markers, as previously reported, although obesity in the present study was also 
Fig re 7. Mass-specific and flux-specific H O2- release from isolated cardiac mitochondria using
either pyruvate and glutamate (PG, panel A and C) or palmityol-carnitine as substrates (PC, panel
B and D) as substrates. Mitochondria were obtained from lean controls (CON) and untreated and
apocynin-treated obese C57BL/6J mice (DIO and DIOAPO) fed a western diet for 28 weeks. Single values
and means ± SEM, * p < 0.05 CON versus DIO, # p < 0.05 DIO vs. DIOAPO.
4. Discussion
In the present study, we only found subtle systemic effects of NOX2-inibition and ablation (KO)
on the development of diet-induced obesity. Reduced NOX2-activity tended to improve insulin
resistance and transiently reduce plasma lipids. It had little effects in fat depots, but tended to reduce
adipose tissue inflammation. However, reduced NOX2 activity did have a marked effect on the
development of cardiac dysfunction and the obesity-induced impaired cardiac energetics. For the
first time, we were able to demonstrate that the obesity-mediated increase in myocardial oxygen
wasting was prevented in both NOX2-KO mice and by NOX2-inhibition with apocynin. We also
demonstrated a possible cross-talk between NOX2-activation and mitochondrial ROS-production,
as has been previously suggested.
Apocynin-treatment and NOX2-ablation have been associated with reduced obesity in several
studies on mice while using different ages, types of obesogenic diets, and feeding periods [30,36–38].
Many studies have also suggested NOX2-derived oxidative stress to be involved in the progression
of obesity and pre-diabetes, through impaired glucose tolerance [30,37,39,40], insulin resistance [39],
dyslipidemia [37,38,40], and visceral adipose inflammation [30,36]. However, there are discrepancies
regarding the systemic effects of NOX2 activity in obesity, with one study also reporting adverse
systemic effects, such as hyperphagia, elevated obesity, hepatic steatosis, and inflammation, together
with exacerbated insulin resistance in obese NOX2 KO mice [41]. The present study does not show major
effects of reduced NOX2 activity on body weight gain while using long term obesogenic diets, but the
data do suggest a transient reduction following the start of the apocynin-treatment. This is in line with
previous studies using shorter feeding periods and similar apocynin-treatments of DIO mice [30,38].
Additionally, reduced NOX2 activity seemed to improve glucose tolerance, reduce hyperlipidemia,
and reduce adipose inflammation following obesity to some degree, in accordance with previous
studies [30,36]. We did not find NOX2 ablation to reduce the expression of these inflammatory markers,
as previously reported, although obesity in the present study was also associated with increased
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hepatic nox2 gene expression and elevated markers of macrophage infiltration and inflammation in
liver [30,38].
Even though the systemic effects of reduced NOX2 activity in obesity were subtle in our hands,
the cardiac effects were more profound. Diabetes and obesity have been shown to increase myocardial
NOX2 activity with both increased expression and recruitment of catalytic subunits to the plasma
membrane and elevated ROS production [8,9,13,14,42,43]. Our data support this by showing elevated
levels of EOH in cardiac tissue in DIO mice, which is primarily a product of increased superoxide.
Apocynin treatment and the ablation of NOX2 partly normalized superoxide derived EOH, but had
no effect on ethidium, suggesting reduced NOX2 activity when compared to reduced NOX4 (which
primarily produces H2O2). Our results are also in line with previous data showing reduced cardiac
NOX2 activity in diabetes and high fat feeding of mice following both the genetic ablation of NOX2 [8,44]
and pharmacological treatment with NOX2-inhibitors [8,11].
In line with previous studies from our group using similar mouse strains, the use of a western
diet seemed to produce more adverse cardiac effects in terms of inducing LV systolic and diastolic
dysfunction [23] when compared to the use of a high fat diet which primarily induced LV diastolic
dysfunction [34]. NOX2 knockout and apocynin-treatment both abrogated the development of
obesity-induced LV dysfunction. This was evident as improved parameters of diastolic and systolic
function and reduced concentric remodeling. Therefore, our results are in accordance with many
studies where genetic and pharmacological strategies to reduce NOX2 activity have been associated
with attenuation of LV dysfunction, pathological remodeling, in models of diabetes [8,9,11,12],
sepsis-induced cardiomyopathy [29], pressure overload [45], and in the aged heart [28].
The present study also confirmed an obesity-mediated impairment of myocardial energetics, as
previously reported in similar DIO models [22,23,34]. In accordance with previous studies [23], oxygen
wasting processes were induced in the myocardium well before the development of LV dysfunction,
as 18 weeks of WD induced elevated MVO2 for non-mechanical work (MVO2unladed) and processes
that are associated with excitation-contraction coupling (MVO2ECC) in the absence LV dysfunction.
Although not significant, the MVO2 used for basal metabolism also tended to be increased, however
we were not able to reproduce previous studies showing the same decrease in mechanical efficiency
or oxygen wasting effects following HFD [23,34,46]. One could speculate that also lean mice on the
standard chow are becoming somewhat obese, and that a shorter feeding period in this mouse strain
could have produced different results, due to the extensive feeding period.
More importantly, we found that the mechanical efficiency was increased, while MVO2unloaded
and MVO2ECC were reduced, suggesting improved cardiac energetics following NOX2 inhibition and
ablation. The exact mechanisms behind obesity-induced myocardial oxygen wasting are not clear,
but the increase in MVO2ECC suggests that impaired calcium handling is a candidate. Many calcium
handling proteins are redox sensitive and their activity may consequently be altered by NOXs [47].
Impaired calcium handling is well documented in diabetic hearts and includes altered sarcoplasmic
reticulum Ca2+-ATPase2 (SERCa2) activity [48], elevated intracellular Ca2+-levels, and increased
ryanodine receptor 2 (RyR2)-leakage [49]. Recently, Joseph et al. [44] reported profound effects of a
short-term saturated high fat diet (SHFD, 4 weeks) of mice on myocardial calcium handling before
the development of both obesity and ventricular structural changes. While SHFD induced heart
rhythm abnormalities in WT mice, this was absent in NOX2 KO hearts and following apocynin
treatment. Additionally, the oxidation of the RYR2 promotes calcium leak and increased calcium sparks,
which were also absent in NOX2 KO hearts from mice that were fed a SHFD [44]. Other studies have
reported a negative impact of NOX2-derived superoxide following acute exposure to FA load [25] and
in other types of heart failure [28]. Our data demonstrating both improved LV function and myocardial
energetics may very well be a functional consequence of the improved calcium handling associated
with reduced NOX2 activity reported in the studies above. Wall stress has also been suggested to
determine myocardial oxygen consumption [50], and it is partly determined by LV pressure. However,
concentric remodeling could also reduce wall stress due to decreased LV radius and increased wall
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thickness. Although the total LV wall stress was not addressed in the current study, one cannot exclude
that attenuated LV remodeling with the reduced LV stiffness observed by NOX2 ablation and inhibition
could have contributed to improved mechanical efficiency.
Diabetes and obesity are associated with increased myocardial FA oxidation rates, which is again
suggested to contribute to an obligatory increase in myocardial oxygen consumption, as the oxidation
of FAs requires more oxygen for the same amount of ATP produced, when compared to glucose.
However, there is evidence that the increased O2 cost for FA oxidation is lacking, and the inhibition
of myocardial FA oxidation does not abolish the increase in MVO2 when hearts are perfused with
high FAs [51,52]. Although we also found that increased FA oxidation in DIO hearts is accompanied
by increased MVO2, we did not find the oxygen sparing effect of apocynin treatment to be linked to
altered myocardial FA oxidation. This again supports that FA oxidation per se has no major role in
altered MVO2.
Several studies have associated diabetes and obesity with cardiac mitochondrial dysfunction,
although there is no complete consensus in the literature [23,24,34]. Elevated, circulating FFA has
been suggested to contribute, as an acute FA load to isolated hearts and cardiomyocytes has been
shown to impair mitochondrial function [24,25]. The observed transient reduction in circulating
FFA following apocynin treatment could very well be a contributor to the observed attenuation of
detrimental cardiac effects. Although NOX2 is situated at the sarcolemma, Joseph et al. [25] found that
both the inhibition and ablation of NOX2 could attenuate lipid-load induced mitochondrial respiratory
dysfunction and mitochondrial ROS-release in cardiomyocytes. Maximal respiratory capacity was
not impaired following obesity in cardiac mitochondria in the present study, but apocynin treatment
was found to increase mitochondrial coupling. Improved mitochondrial coupling can be beneficial in
terms of reducing oxygen-wasting processes for basal metabolism, and, therefore, could contribute
to the reduced MVO2unloaded observed following NOX2 ablation and inhibition in the present study.
Although apocynin has been reported to exhibit direct antioxidant properties in vascular systems [53],
it is extensively used as an inhibitor of myocardial NOX2 activity in many studies. Our data also
support reduced myocardial NOX2 activity to be associated with reduced cardiac mitochondrial
ROS release [25,54]. The apocynin-mediated reduction in ROS could contribute to the improved
mitochondrial coupling in mitochondria from these hearts, as ROS have been shown to activate
mitochondrial uncoupling proteins [55].
5. Conclusions
In line with previous studies on other models of heart failure, this study demonstrates that
ablation and inhibition of NOX2 both attenuated obesity-induced left ventricular remodeling and
dysfunction. Reduced NOX2 activity was also associated with improved myocardial energetics
that could be attributed to decreased myocardial oxygen consumption for non-mechanical work,
including processes that are associated with excitation-contraction coupling. Myocardial substrate
utilization and mitochondrial respiratory capacity was not profoundly affected by NOX2 inhibition,
but obesity-induced mitochondrial ROS production was abrogated.
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